Intratumoural immunotherapies in oncology

Although immune checkpoint inhibitors have become the standard of care for many tumours, the majority of patients fail to achieve sustained benefit, often owing to the lack of a T-cell inflamed tumour microenvironment (TME). Directly injected intratumoural therapies present a potential strategy to induce T-cell inflammation and convert a ‘cold’ immune-inert TME into a ‘hot’ immune-inflamed TME. Various approaches including chemoablation, oncolytic viral therapy, cytokines and agents targeting innate immunity such as Toll-like receptor agonists and stimulator of interferon genes agonists are in clinical development.

Source: European Journal of Cancer - January 17, 2020 Category: Cancer & Oncology Authors: Wen Xu, Victoria G. Atkinson, Alexander M. Menzies Tags: Current Perspective Source Type: research